NASDAQ:BYSIBeyondspring Stock Price, Forecast & News

Beyondspring's stock was trading at $11.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BYSI stock has increased by 34.4% and is now trading at $15.26. View which stocks have been most impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Beyondspring.

Beyondspring is scheduled to release its next quarterly earnings announcement on Wednesday, September 16th 2020. View our earnings forecast for Beyondspring.

Beyondspring Inc (NASDAQ:BYSI) posted its earnings results on Thursday, June, 11th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.08. View Beyondspring's earnings history.

4 brokers have issued 12 month target prices for Beyondspring's stock. Their forecasts range from $25.00 to $46.00. On average, they anticipate Beyondspring's stock price to reach $35.00 in the next year. This suggests a possible upside of 129.4% from the stock's current price. View analysts' price targets for Beyondspring.

Headlines about BYSI stock have been trending neutral this week, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Beyondspring earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Beyondspring.

Some companies that are related to Beyondspring include Eidos Therapeutics (EIDX), Dicerna Pharmaceuticals (DRNA), Ligand Pharmaceuticals (LGND), Xencor (XNCR), Prestige Consumer Healthcare (PBH), Aurinia Pharmaceuticals (AUPH), Myovant Sciences (MYOV), Madrigal Pharmaceuticals (MDGL), I-Mab (IMAB), Akebia Therapeutics (AKBA), Intra-Cellular Therapies (ITCI), Y-mAbs Therapeutics (YMAB), Zymeworks (ZYME), Ironwood Pharmaceuticals (IRWD) and INDIVIOR PLC/S (INVVY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Beyondspring investors own include Exelixis (EXEL), Enterprise Products Partners (EPD), Intel (INTC), AbbVie (ABBV), Gilead Sciences (GILD), Johnson & Johnson (JNJ), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), Crispr Therapeutics (CRSP) and Enbridge (ENB).

(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.

Beyondspring trades on the NASDAQ under the ticker symbol "BYSI."

Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BYSI stock can currently be purchased for approximately $15.26.

Beyondspring has a market capitalization of $459.48 million. The company earns $-38,080,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

The official website for Beyondspring is www.beyondspringpharma.com.

Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]